ACTRN12620000213943已完成1 期
A Phase 1, randomized, Double-Blind, Placebo-Controlled study to evaluate the Safety, Tolerability and Pharmacokinetics of single and multiple ascending doses of Ultramicronized PEA in normal healthy volunteers.
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 48
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomised controlled trial
- 主要目的
- Treatment
- 盲法
- Blinded (masking used)
入排标准
- 年龄范围
- 18 Years 至 65 Years（—）
- 性别
- All
入选标准
- •1. Male or female, light smoker (no more than 9 cigarettes or equivalent daily) or non-smoker, healthy subjects, aged 18 to 65 years inclusive.
- •2. Healthy is defined as
- •a)the absence of clinically significant illness and surgery within 4 weeks prior to study drug administration.
- •b)the absence of clinically significant history of neurological, endocrine, cardiovascular, respiratory, hematological, immunological, psychiatric, gastrointestinal, renal, hepatic, and metabolic disease.
- •3. Body mass index of >18.5 to <32.0 kg/m2.
- •4. Females of childbearing potential who are sexually active with a non-sterile male partner (sterile male partners are defined as men vasectomized since at least 6 months) must be willing to use one of the following acceptable contraceptive methods throughout the study and for 30 days after (the last) study drug administration:
- •a)simultaneous use of intra-uterine contraceptive device, placed at least 4 weeks prior to (the first) study drug administration, and condom for the male partner.
- •b)simultaneous use of hormonal contraceptives, started at least 4 weeks prior to (the first) study drug administration and must agree to use the same hormonal contraceptive throughout the study, and condom for the male partner.
- •c)simultaneous use of diaphragm or cervical cap and male condom for the male partner, started at least 21 days prior to (the first) study drug administration.
- •5. Male subjects who are not vasectomized for at least 6 months, and who are sexually active with a female partner of childbearing potential (childbearing potential females are defined as women that are neither post-menopausal nor surgically sterile) must be willing to use one of the following acceptable contraceptive methods from (the first) study drug administration and for 90 days after (the last) study drug administration:
- •a)simultaneous use of a male condom and, for the female partner, intra-uterine contraceptive device or hormonal contraceptives used since at least 4 weeks.
- •b)simultaneous use of a male condom and, for the female partner, a diaphragm or cervical cap.
- •6. Male subjects (including men who have had a vasectomy) with a pregnant partner must agree to use a condom from (the first) study drug administration and for 90 days after (the last) study drug administration.
- •7. Male subjects must be willing not to donate sperm for 90 days following (the last) study drug administration.
- •8. Capable of consent.
排除标准
- •1.Any clinically significant abnormality at physical examination.
- •2. Any laboratory test results deemed clinically significant by the Investigator or positive test for HIV, HBsAg, or HCV found during medical screening.
- •3. Positive pregnancy test at screening or Day 1.
- •4. Positive urine drug screen or alcohol breath test at screening or Day 1.
- •5. History of allergic reactions to PEA or other related drugs, or to any excipient in the formulation.
- •6. Clinically significant ECG abnormalities or vital sign abnormalities (systolic BP lower than 90 or over 140 mmHg, diastolic BP lower than 40 or over 90 mmHg, HR less than 40 or over 100 bpm, or RR less than 10 or over 22 bpm) at screening.
- •7. History of significant drug abuse within 1 year prior to screening or use of soft drugs (such as marijuana) within 1 month prior to the screening or hard drugs (such as cocaine, phencyclidine [PCP], crack, opioid derivatives including heroin, and amphetamine derivatives) within 3 months prior to screening.
- •8. History of significant alcohol abuse within 1 year prior to screening or regular use of alcohol within 6 months prior to the screening visit (more than 14 units of alcohol per week [1 unit equals to 150 mL of wine, 360 mL of beer, or 45 mL of 40% alcohol]).
- •9. Participation in a clinical research study involving the administration of an investigational or marketed drug or device within 30 days prior to the first dosing, administration of a biological product in the context of a clinical research study within 90 days prior to the first dosing, or concomitant participation in an investigational study involving no drug or device administration.
- •10. Use of medications for the timeframes specified below, with the exception of hormonal contraceptives and medications exempted by the Investigator on a case-by-case basis because they are judged unlikely to affect the PK profile of the study drug or subject safety (e.g., topical drug products without significant systemic absorption):
- •a)prescription medications within 14 days prior to (the first) dosing;
- •b)over-the-counter products and natural health products (including herbal remedies such as St. John’s wort, homeopathic and traditional medicines, probiotics, food supplements such as vitamins, minerals, amino acids, essential fatty acids, and protein supplements used in sports) within 7 days prior to (the first) dosing, with the exception of the occasional use of acetaminophen (up to 2 g daily);
- •c)depot injection or implant of any drug (other than hormonal contraceptives) within 3 months prior to (the first) dosing;
- •11. Donation of plasma within 7 days prior to dosing. Donation or loss of blood (excluding volume drawn at screening) of 50 mL to 499 mL of blood within 30 days, or more than 499 mL within 56 days prior to the first dosing.
- •12. Breast-feeding subject.
- •13. Any reason which, in the opinion of the Investigator, would prevent the subject from participating in the study.
研究者
相似试验
已完成
1 期
A Study of Clofazimine Inhalation Suspension (MNKD-101) in Healthy VolunteersPulmonary Nontuberculous Mycobacteria InfectionsInfection - Other infectious diseasesACTRN12621001702808MannKind Corporation40
招募中
1 期
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BW-20805 in Healthy SubjectsHereditary angioedemaACTRN12623000689673Argo Biopharma Australia Pty Ltd32
已完成
1 期
An interventional study to assess the safety, pharmacokinetic (PK, the measure of how the human body processes a substance) response and tolerability (how well a substance is tolerated by participants) to Zolmitriptan following multiple oral doses in Adult Healthy VolunteersAutismACTRN12620000234910Maplight therapeutics41
已完成
1 期
Safety and tolerability Phase I study of LBS-008 in healthy adult subjects after single and multiple dosesDry age-related macular degenerationEye - Normal eye development and functionACTRN12618001823268RBP4 Pty Ltd71
已完成
1 期
Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single Rising Dose Study of AR882 in Healthy Adult Male VolunteersHyperuricemiaACTRN12619000021178Arthrosi Therapeutics Australia Pty, Ltd a subsidiary of Arthrosi Therapeutics, Inc.63